Coronavirus Update: Inside Moderna's Deal With The US
Plus: Generex Forges Vaccine Partnership
Company receives a base payment of $1.225bn for the manufacturing and delivery of the first 100 million disease, plus a bonus if mRNA-1273 reaches the market quickly.
You may also be interested in...
Analysts have cut forecasts for Moderna’s COVID-19 vaccine – but there is still much to play for as key readouts approach.
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.